Literature DB >> 1989819

Spontaneous pneumothorax in AIDS patients with recurrent Pneumocystis carinii pneumonia despite aerosolized pentamidine prophylaxis.

D J Shanley1, B A Luyckx, M F Haggerty, T F Murphy.   

Abstract

Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS) may predispose these patients to recurrent apical Pneumocystis infection. Bullous changes and pulmonary cysts develop in the lung apices due to repeated episodes of inflammation and cytotoxic effects of HIV on pulmonary macrophages. These changes progress despite prophylaxis against recurrent Pneumocystis infection with aerosolized pentamidine, increasing the risk of spontaneous pneumothorax. Two cases are presented of bilateral pneumothoraces in patients with AIDS and recurrent P carinii pneumonia despite aerosolized pentamidine prophylaxis. Patients receiving aerosolized pentamidine prophylaxis for Pneumocystis pneumonia appear to have an increased risk of pneumothorax due to recurrent apical infections with P carinii.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989819     DOI: 10.1378/chest.99.2.502

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Breathlessness in a drug user.

Authors:  Ivan Yeu Ming Yip
Journal:  BMJ Case Rep       Date:  2015-05-02

Review 2.  Human immunodeficiency virus infection and pneumothorax.

Authors:  Eirini Terzi; Konstantinos Zarogoulidis; Ioanna Kougioumtzi; Georgios Dryllis; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Theodora Tsiouda; Athanasios Madesis; Theodoros Karaiskos; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

4.  Targeting drug delivery to the lungs by inhalation.

Authors:  C O'Callaghan
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.